These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 33450528)

  • 1. Babesia microti infection in a patient with multiple sclerosis treated with ocrelizumab.
    Haberli N; Coban H; Padam C; Montezuma-Rusca JM; Creed MA; Imitola J
    Mult Scler Relat Disord; 2021 Feb; 48():102731. PubMed ID: 33450528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab.
    Auer M; Bsteh G; Hegen H; Wurth S; Zinganell A; Berger T; Deisenhammer F; Pauli FD
    Mult Scler Relat Disord; 2020 Aug; 43():102155. PubMed ID: 32470856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population.
    Coban H; Germaine S; Dimaandal I; Haberli N; Padam C; Creed MA; Imitola J
    Mult Scler Relat Disord; 2021 Aug; 53():103021. PubMed ID: 34077828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocrelizumab and Other CD20
    Gelfand JM; Cree BAC; Hauser SL
    Neurotherapeutics; 2017 Oct; 14(4):835-841. PubMed ID: 28695471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocrelizumab for the treatment of multiple sclerosis.
    Bigaut K; De Seze J; Collongues N
    Expert Rev Neurother; 2019 Feb; 19(2):97-108. PubMed ID: 30570368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B cell depletion in the treatment of multiple sclerosis.
    Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
    Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ocrelizumab for treatment of multiple sclerosis].
    Graf J; Albrecht P; Goebels N; Aktas O; Hartung HP
    Nervenarzt; 2020 Aug; 91(8):722-734. PubMed ID: 32524163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dengue fever in a multiple sclerosis patient taking Ocrelizumab.
    Guerra T; Bollo L; Trojano M; Iaffaldano P
    Mult Scler; 2021 Nov; 27(13):2116-2118. PubMed ID: 34449289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral pericarditis following ocrelizumab in a multiple sclerosis patient.
    Miele G; Abbadessa G; Maida E; Bonavita S
    Neurol Sci; 2023 Aug; 44(8):2947-2949. PubMed ID: 37095363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Splenic Rupture as the First Manifestation of Babesia Microti Infection: Report of a Case and Review of Literature.
    Dumic I; Patel J; Hart M; Niendorf ER; Martin S; Ramanan P
    Am J Case Rep; 2018 Mar; 19():335-341. PubMed ID: 29567936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute pancreatitis after ocrelizumab treatment for relapsing remitting multiple sclerosis.
    Adamec I; Reiner Ž; Pećin I; Šućur N; Godan Hauptman A; Barun B; Gabelić T; Habek M
    Mult Scler Relat Disord; 2020 Oct; 45():102381. PubMed ID: 32653735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [B-cell depletion in the therapy of multiple sclerosis: ofatumumab is a new player].
    Pukoli D; Vécsei L
    Ideggyogy Sz; 2022 May; 75(5-06):163-169. PubMed ID: 35819344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients.
    Gingele S; Jacobus TL; Konen FF; Hümmert MW; Sühs KW; Schwenkenbecher P; Ahlbrecht J; Möhn N; Müschen LH; Bönig L; Alvermann S; Schmidt RE; Stangel M; Jacobs R; Skripuletz T
    Cells; 2018 Dec; 8(1):. PubMed ID: 30597851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.
    Sorensen PS; Blinkenberg M
    Ther Adv Neurol Disord; 2016 Jan; 9(1):44-52. PubMed ID: 26788130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutropaenia complications from Ocrelizumab and Rituximab treatment.
    Pang V; Seery N; Wesselingh R; Yeh W; Zhong M; Tan T; Dwyer C; Nesbitt C; Rath L; Perera D; Bridge F; Skibina O; Bosco JJ; Jokubaitis V; Marriott M; Butkueven H; Van Der Walt A; Massey J; Sutton I; Monif M
    Mult Scler Relat Disord; 2024 Jan; 81():105147. PubMed ID: 38043368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
    Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
    Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Congenital Babesiosis After Maternal Infection With Borrelia burgdorferi and Babesia microti.
    Saetre K; Godhwani N; Maria M; Patel D; Wang G; Li KI; Wormser GP; Nolan SM
    J Pediatric Infect Dis Soc; 2018 Feb; 7(1):e1-e5. PubMed ID: 28992325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ocrelizumab-associated severe neutropenia: an underestimated complication of treatment of multiple sclerosis with anti-CD20 antibodies?].
    Hess F; Uibel P; Berthele A; Hemmer B
    Nervenarzt; 2023 Dec; 94(12):1153-1156. PubMed ID: 37294304
    [No Abstract]   [Full Text] [Related]  

  • 19. Two cases of meningitis associated with ocrelizumab therapy.
    Theriault M; Solomon AJ
    Mult Scler Relat Disord; 2020 Feb; 38():101866. PubMed ID: 31821962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG).
    Kostka J; Maharjan AS; Kumar S; Hackenyos D; Krause PJ; Dieckhaus K
    PLoS Negl Trop Dis; 2024 Mar; 18(3):e0012035. PubMed ID: 38484010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.